Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
about
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisLurasidone for the treatment of bipolar depression: an evidence-based reviewManagement of bipolar I depression: clinical utility of lurasidoneIloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapyCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewAn evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapineA review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic ReviewsSafety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management.Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approachSexually dimorphic, developmental, and chronobiological behavioral profiles of a mouse mania model.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Asenapine in bipolar I disorder: evidence and place in patient management.Behavioral interventions for antipsychotic induced appetite changes.Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis.New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania.Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled studyThe prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controlsSwitching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional studyLong-term efficacy and safety of iloperidone: an update.Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.Weight considerations in psychotropic drug prescribing and switching.Safety profile of iloperidone in the treatment of schizophrenia.Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism.Weight gain and antipsychotics: a drug safety review.Diabetes mellitus and severe mental illness: mechanisms and clinical implications.Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management.Type 2 diabetes in children and adolescents on atypical antipsychotics.Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis.Managing comorbid obesity and depression through clinical pharmacotherapies.Depot risperidone-induced adverse metabolic alterations in female rats.Asenapine: A Review in Schizophrenia.Asenapine for the Treatment of Psychotic Disorders.Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.Pharmacogenomics of autism spectrum disorder.
P2860
Q24606868-FCAECE1A-50A9-438E-93C9-DA485AF0CC62Q26796437-C8A298CC-04B0-4E4B-BF81-0C26D72E72F6Q27012673-8BA430D9-2304-4069-9026-6F044CE2183AQ28078158-F99D80A4-25D7-43E3-A0C8-4EAB44DE50CEQ28079821-9EBAB3D7-9582-442B-9FB3-49C66EF69A67Q28543222-CCB801AF-CCFC-42F3-A82C-38B227889BFCQ30353864-79C4B198-9417-4A2C-8F11-70C97E124217Q33619940-08285C20-C67F-43F1-BE10-10636599621FQ33716263-5BFF0C9C-5F3D-456A-B606-F66E6D8AD20CQ33878816-43F6D633-26E3-41F8-B769-BB8A34F6D1ABQ34073723-162C55E8-6C5E-4318-AF33-8BFBA7BE1610Q34292768-4DDBE023-D8FA-44DD-8A6F-117651487B18Q34464293-349D5C69-516D-4CC7-A05A-38DD9D4D346DQ34964892-D7B2BC18-62C9-40AA-813F-3FF58C6A7968Q35754726-153946EE-422B-4F6F-AC56-65246208F9A4Q36515504-1DDD4FEE-011D-4F70-AF97-31760F47C104Q36651040-9B140BC1-1BF3-47B1-910D-58E489724F0FQ36852489-26D69B46-5C97-468A-9654-FEB5CBC844D2Q36929705-64AFA83D-3C5D-4CAF-BE7E-903AA178D3FCQ37030153-25B04009-C400-4D66-814C-7DD512DA09B2Q37079080-ACB29C95-C7D2-4D0D-B7F8-111EB31F814CQ37236162-62180E02-7342-4360-BD71-3F272E2FFC21Q37547469-4809EBCF-2C90-4A24-A459-4B14C9F615D9Q37616980-E94E52EE-F5F8-4075-8C12-F64078266448Q38070179-323DB37B-E64E-4FAE-83C1-CEE7887FE60CQ38151453-7A15EDE3-BAA6-4324-919B-0C2CC5F78A96Q38160942-95DF3724-FCB2-48C7-8A71-DCF59BD68BDEQ38209103-4D64602F-67D8-4A14-A779-74E7843F5B51Q38268590-C8882368-3C6E-4126-98B4-B6F09DEB6506Q38274901-930EF005-96C2-4CB4-BB3F-A6A47B11696DQ38473914-3F80A447-4097-4ABB-82D3-F4EE206FC61BQ38504254-63442909-931D-44C3-9A22-80B314A53E55Q38530458-5D1AE63D-0604-4632-9926-7ED43CCB499DQ38749110-8318A787-78B7-42B0-B30F-44A8B401B9E8Q38859885-94F5C3BB-4959-46EA-8F20-5EACB43226CAQ38873420-3178A4F5-C198-405B-9398-12625F8C74F4Q38880899-2A33C228-B010-4A3D-B24F-317384882B11Q38915815-99CAC724-F81F-468D-B17A-061924A1E2CBQ39009497-496C3D2F-DF4E-4819-812E-D923C32D248DQ39154436-377ADAC2-BFE6-424A-B2EC-FA11AE358460
P2860
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Body weight and metabolic adve ...... and exploratory meta-analysis.
@ast
Body weight and metabolic adve ...... and exploratory meta-analysis.
@en
Body weight and metabolic adve ...... and exploratory meta-analysis.
@nl
type
label
Body weight and metabolic adve ...... and exploratory meta-analysis.
@ast
Body weight and metabolic adve ...... and exploratory meta-analysis.
@en
Body weight and metabolic adve ...... and exploratory meta-analysis.
@nl
prefLabel
Body weight and metabolic adve ...... and exploratory meta-analysis.
@ast
Body weight and metabolic adve ...... and exploratory meta-analysis.
@en
Body weight and metabolic adve ...... and exploratory meta-analysis.
@nl
P2093
P2860
P921
P1433
P1476
Body weight and metabolic adve ...... and exploratory meta-analysis.
@en
P2093
Christoph U Correll
Johan Detraux
Kim Sweers
Marc De Hert
Ruud van Winkel
Weiping Yu
P2860
P304
P356
10.2165/11634500-000000000-00000
P577
2012-09-01T00:00:00Z
P5875
P6179
1007795480